ALK and non-small cell lung carcinoma: The efficacies of chemotherapy, first-generation ALK inhibitors (crizotinib), second-generation ALK inhibitors (ceritinib, alectinib, brigatinib, and ensartinib), and third-generation ALK inhibitors (lorlatinib) in prolonging PFS were compared between generations in the overall patient population of ALK-p, ALK inhibitor-naive advanced NSCLC.